We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
| No holders yet. | ||||||||||
Energesis Pharmaceuticals leads in utilizing brown adipose tissue to combat obesity and diabetes. This biopharmaceutical company specializes in discovering and developing drugs for obesity, diabetes, and related metabolic diseases. Their flagship program, EGS2632, activates brown adipose tissue (BAT) to promote weight loss similar to GLP-1 therapies, focusing on boosting energy expenditure rather than reducing intake in the weight maintenance equation.